Oncology nurses and APPs provide support and can help to facilitate conversations with patients and families during end-of-life care.

Updated MAIA trial results reinforce the frontline benefit of daratumumab plus lenalidomide/dexamethasone in transplant-ineligible NDMM.

The FDA has approved treatment with pembrolizumab plus trastuzumab and chemotherapy for HER2+ gastric/GEJ adenocarcinoma with PD-L1 CPS of 1 or greater.

In myeloma treatment, acute CRS is a common but treatable AE associated with CAR T-cell therapy and bispecific antibodies, according to a nurse practitioner.

Alternating post-HCT care between specialized facilities and local cancer centers produced noninferior non-relapse mortality and similar quality of life to usual care.

Restaging cancer can be an unfamiliar space, but with more experience, APPs can rely less on MDs for guidance in such cases.

Cema-cel was associated with largely durable CRs in patients with CD19 CAR T-cell therapy-naïve relapsed/refractory LBCL.

Experts discuss the patient case of Janet, a 58-year-old with her 2 positive metastatic breast cancer, and after 14 months on the Cleopatra regimen with taxane, Trastuzumab, and Pertuzumab, and 11 months on Tdxd. As her disease is now progressing, so she needs 3rd line treatment. But despite some fatigue, she remains active with work and Yoga and her brain, MRIs are clear.

While ambient particle levels differed by HEPA filter status, Splashblocker significantly reduced particles emitted from toilet plume aerosols regardless.

Working with multidisciplinary teams and educating patients are key to treating patients with cancer while navigating newly approved treatments.

The phase 3 COMPETE trial found that ITM-11 met its primary PFS end point and demonstrated a positive trend in OS for patients with GEP-NETs.

A phase 2 trial found that pembrolizumab plus pemetrexed met its objective response rate primary end point.

Working with interdisciplinary teams and nurse navigators to coordinate care across specialties is a facet of oncology nursing that may be overlooked, says an expert.

Palbociclib plus letrozole lengthened PFS vs placebo plus letrozole for patients with ER-positive advanced or recurrent endometrial cancer.

Experts discuss how to balance treatment intensity with maintaining quality of life, particularly in patients with advanced-stage disease.

Experts discuss effective communication strategies for managing patient and caregiver expectations about treatment adverse effects and their potential impact on daily life.

Patricia Jakel, MN, RN, AOCN, emphasized that the bond oncology nurses have with patients with cancer necessitates honest and often difficult conversations.

Two denosumab biosimilars have been approved by the FDA for all previously approved uses for the reference drugs in cancers and osteoporosis.

A recent study found that toxicity is routinely minimized in phase 3 oncology trials, especially those that are not industry sponsored.

Adding antihistamines to atezolizumab led to a 46% OS rate and a 23% PFS rate in metastatic urothelial carcinoma.

Key opinion leaders compare lorlatinib’s side effect profile to other ALK inhibitors, highlighting unique challenges and benefits observed in clinical practice.

Key opinion leaders discuss effective multidisciplinary strategies for managing the range of side effects associated with ALK inhibitors.

Panitumumab plus ipilimumab and nivolumab signaled complete or partial response in 18 patients with KRAS/NRAS/BRAF wild-type MSS mCRC at the 12-week mark.

Jessie Desir, PhD, RN, AMB-BC, OCN, discussed the need for awareness about cancer subtypes and their prevalence in certain populations.